Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CSF1R
REST API REST API
Homo sapiens
CSF1R is differentially expressed in 222 experiments: 128 organism parts: placenta, cerebellum, ... (126 more);, 202 disease states: normal, acute myeloid leukemia, ... (200 more);, 78 cell types 142 cell lines 30 compound treatments and 54 other conditions.
Synonyms CD115, CSFR, C-FMS, FMS
Orthologs Csf1r (Mus musculus)   Q90959_CHICK (Gallus gallus)   csf1ra (Danio rerio)   csf1rb (Danio rerio)   A7Z067_BOVIN (Bos taurus)   Csf1r (Rattus norvegicus)   Pvr (Drosophila melanogaster)   csf1r (Xenopus laevis)   CSF1R (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, cell proliferation, membrane, protein tyrosine kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, ATP binding, transferase activity, transferring phosphorus-containing groups, multicellular organismal development, integral to plasma membrane, cytokine binding, receptor activity, nucleotide binding, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, protein homodimerization activity, integral to membrane, signal transduction, protein kinase activity, receptor complex, protein phosphorylation, macrophage colony-stimulating factor receptor activity
InterPro Term Ig_sub, Immunoglobulin, Prot_kinase_cat_dom, Ig-like, Ig_sub2, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Tyr_kinase_CSF1/PDGF_rcpt, Se/Thr_kinase-like_dom
UniProt Accession P07333, Q6LEI2, B5A955, D6RGW1, Q59HE0, E9PEK4
Search EB-eye ENSG00000182578
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-22639, E-GEOD-847, E-GEOD-24147, ... (24 experiments)

Factor Value U/D Experiments
HCC1187
1
E-MTAB-62
GM14153
1
E-TABM-321
HMCB
1
E-MTAB-37
NA19190
1
E-GEOD-19480
NCIH838
1
E-MTAB-37
NCIH2347
1
E-MTAB-37
136 more value(s).


Cell type

studied in E-MEXP-1242, E-GEOD-22529, E-GEOD-22373, E-GEOD-3920, E-GEOD-20677, ... (39 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
whole blood
2
E-GEOD-3026, E-MTAB-25
stromal cell
1
E-MEXP-1327
leydig cell
1
E-MTAB-25
immortalised T lymphocytes
1
E-GEOD-13909
72 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-TABM-15, E-MTAB-62, ... (62 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MTAB-62, E-MEXP-1327, E-MEXP-2034
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
colon carcinoma
2
E-MTAB-62, E-MTAB-37
presymptomatic DMD
1
E-MTAB-62
196 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-TABM-868, ... (23 experiments)

Factor Value U/D Experiments
lipopolysaccharide
1
2
E-GEOD-3140, E-MEXP-1958, E-TABM-868
vanadium pentoxide
1
E-GEOD-5339
TNF
1
E-GEOD-15205
baseline sevoflurane
1
E-GEOD-4386
resveratrol
1
E-TABM-782
LDL
1
E-GEOD-5741
24 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-MTAB-69, ... (8 experiments)

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-108, E-GEOD-361

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-2292, E-TABM-321, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1446, E-MEXP-1103, E-MEXP-2146

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-GEOD-16363, ... (26 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-MEXP-101

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-TABM-147

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541

Processing time: 0.356 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM